Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-21
    E.g., 2018-06-21


19304 items
5:03 PM, May 18, 2018  |  BioCentury | Politics, Policy & Law

Shifting parts

HHS Secretary Alex Azar is convinced that the way Medicare Part B spends money for drugs makes no sense, costs the taxpayers too much and isn’t good for patients. He says he’s open to suggestions...
2:15 PM, May 18, 2018  |  BioCentury | Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of investors...
1:40 PM, May 18, 2018  |  BioCentury | Finance

CellCentric’s magic trio

Five years after pivoting from target discovery to drug development, epigenetics play CellCentric Ltd. is taking its sole asset CCS1477 into the clinic next month with $26 million from Morningside Venture Investments. The company believes...
1:06 PM, May 18, 2018  |  BioCentury | Finance

Ansun’s China ambitions

The China-heavy syndicate behind Ansun BioPharma Inc.’s $85 million series A round reflects the San Diego-based antiviral company’s long-term plans to penetrate the China market. Sinopharm Healthcare Fund and Lilly Asia Ventures led the round, with...
2:09 AM, May 18, 2018  |  BioCentury | Emerging Company Profile

Accent on RNA

With its debut Friday with a $40 series A, Accent Therapeutics Inc. became the second disclosed newco to jump into the nascent arena of RNA epigenetics. The biotech has identified enzymes it believes drive cancer...
4:43 PM, May 15, 2018  |  BioCentury | Finance

Single Celsius

After identifying its first targets, Third Rock Ventures newco Celsius Therapeutics emerged from stealth with a $65 million series A round to apply single-cell genomics techniques to drug development for autoimmune diseases and cancer. GV,...
6:18 PM, May 11, 2018  |  BioCentury | Finance

HKEX opportunity knocking

The rapid growth of biotech in the greater China region is something Jefferies does not intend to miss. With the opening of a new biotech chapter on the Hong Kong Exchanges and Clearing Ltd. on April...
5:25 PM, May 11, 2018  |  BioCentury | Politics, Policy & Law

Getting reorganized

FDA is reorganizing the Office of New Drugs in its Center for Drug Evaluation and Research, seeking to make review oversight more consistent while encouraging senior staff to become thought leaders. The changes at OND...
4:17 PM, May 11, 2018  |  BioCentury | Finance

Aslan’s insiders

A disappointing offering on NASDAQ by Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) looks to be the consequence of Taiwan exchange rules that prevented more robust insider participation. So even though big names such as Morningside and...
3:55 PM, May 11, 2018  |  BioCentury | Strategy

Takeda hits the gas

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management. On May 8,...